Management of toxicities and optimal dosing of targeted drugs in advanced kidney cancer

Abstract

Toxicities of new targeted drugs may diminish their effectiveness in advanced kidney cancer if they are not recognized and addressed properly early in patient treatment. Most of the drug-related toxicities in advanced kidney cancer are managable with supportive care without a need for long interruptions, dose reductions or permanent discontinuation of the treatment.